Osteoporosis following heart transplantation and immunosuppressive therapy
(2017) In Transplantation Reviews 31(4). p.232-239- Abstract
Heart transplantation (HT) remains the ultimate final therapy for patients with end-stage heart failure, who despite optimal medical and surgical treatments exhibit severe symptoms. To prevent rejection of the transplanted organ, HT patients require life-long immunosuppressive therapy. The goal of the immunosuppression is to minimise the risk of immune-mediated graft rejection, while avoiding clinical side-effects. Current immunosuppressive agents have yielded good survival outcome, however, complications of the immunosuppressive therapy, such as impaired bone strength and increased fracture risk, are common among HT patients rendering increased morbidity and mortality rates. The main aim of the present review was to summarise current... (More)
Heart transplantation (HT) remains the ultimate final therapy for patients with end-stage heart failure, who despite optimal medical and surgical treatments exhibit severe symptoms. To prevent rejection of the transplanted organ, HT patients require life-long immunosuppressive therapy. The goal of the immunosuppression is to minimise the risk of immune-mediated graft rejection, while avoiding clinical side-effects. Current immunosuppressive agents have yielded good survival outcome, however, complications of the immunosuppressive therapy, such as impaired bone strength and increased fracture risk, are common among HT patients rendering increased morbidity and mortality rates. The main aim of the present review was to summarise current knowledge on bone strength impairment after HT and concomitant immunosuppressive therapy.
(Less)
- author
- Löfdahl, Eveline LU and Rådegran, Göran LU
- organization
- publishing date
- 2017-08-12
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Transplantation Reviews
- volume
- 31
- issue
- 4
- pages
- 232 - 239
- publisher
- Elsevier
- external identifiers
-
- scopus:85028612208
- pmid:28865930
- wos:000416196900002
- ISSN
- 0955-470X
- DOI
- 10.1016/j.trre.2017.08.002
- language
- English
- LU publication?
- yes
- id
- 793a2f50-9aa5-4fa7-94f1-151d6493303a
- date added to LUP
- 2017-10-04 16:38:00
- date last changed
- 2024-06-10 00:41:49
@article{793a2f50-9aa5-4fa7-94f1-151d6493303a,
abstract = {{<p>Heart transplantation (HT) remains the ultimate final therapy for patients with end-stage heart failure, who despite optimal medical and surgical treatments exhibit severe symptoms. To prevent rejection of the transplanted organ, HT patients require life-long immunosuppressive therapy. The goal of the immunosuppression is to minimise the risk of immune-mediated graft rejection, while avoiding clinical side-effects. Current immunosuppressive agents have yielded good survival outcome, however, complications of the immunosuppressive therapy, such as impaired bone strength and increased fracture risk, are common among HT patients rendering increased morbidity and mortality rates. The main aim of the present review was to summarise current knowledge on bone strength impairment after HT and concomitant immunosuppressive therapy.</p>}},
author = {{Löfdahl, Eveline and Rådegran, Göran}},
issn = {{0955-470X}},
language = {{eng}},
month = {{08}},
number = {{4}},
pages = {{232--239}},
publisher = {{Elsevier}},
series = {{Transplantation Reviews}},
title = {{Osteoporosis following heart transplantation and immunosuppressive therapy}},
url = {{http://dx.doi.org/10.1016/j.trre.2017.08.002}},
doi = {{10.1016/j.trre.2017.08.002}},
volume = {{31}},
year = {{2017}},
}